白蛋白结合型紫杉醇二线治疗晚期非小细胞肺癌的临床效果观察  

Clinical effect of nanoparticle albumin-bound paclitaxel as the second-line treatment of advanced nonsmall cell lung cancer

作　　者：陈斌[1] CHEN Bin(Wuxi Second People’s Hospital,Wuxi 214000,China)

机构地区：[1]无锡市第二人民医院,214000

出　　处：《中国现代药物应用》2020年第20期4-6,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探究白蛋白结合型紫杉醇(Nab-P)二线治疗晚期非小细胞肺癌(NSCLC)的临床效果。方法选择49例晚期NSCLC患者作为研究对象,实施Nab-P单药治疗。统计分析其临床疗效、不良发反应发生情况、生命质量情况。结果49例患者均按计划完成了全部治疗,化疗周期为2~12个,平均化疗周期(8.2±3.8)个。其中0例完全缓解(CR)、13例部分缓解(PR)、21例疾病稳定(SD)、15例疾病进展(PD),疾病控制率(DCR)为69.4%。患者中位无进展生存时间为5.2个月;中位生存时间为40.2个月。49例患者在Nab-P单药治疗中均表现出较好的耐受性。患者不良反应主要包括血小板减少、乏力、中性粒细胞减少、恶性呕吐、周围神经毒性等,以0~2级不良反应为主,未出现严重不良反应。患者生命质量收益为34.7%(17/49),其中,3例明显改善、14例改善、29例稳定、3例降低。结论在晚期NSCLC患者二线治疗中,Nab-P单药治疗效果明显,能够减少患者生存期治疗中不良反应发生,对于提高患者生命健康质量、延长生存期起到了良好效果,值得临床推广应用。Objective To investigate the clinical effect of nanoparticle albumin-bound paclitaxel(Nab-P)as the second-line treatment of advanced non-small cell lung cancer(NSCLC).Methods 49 patients with advanced NSCLC were selected as the research subjects and implemented Nab-P monotherapy.The clinical efficacy,adverse reactions,quality of life were statistically analyzed.Results All the 49 patients completed the treatment according to the plan.The chemotherapy cycle was 2-12 cycles,with an average of(8.2±3.8)cycles.There were 0 case of complete remission(CR),13 cases of partial remission(PR),21 cases of stable disease(SD)and 15 cases of progressive disease(PD),and the disease control rate(DCR)was 69.4%.The median progressionfree survival time of patients was 5.2 months;the median survival time was 40.2 months.49 patients showed good tolerance in Nab-P monotherapy.The adverse reactions of patients mainly included thrombocytopenia,fatigue,neutropenia,malignant vomiting,peripheral neurotoxicity,etc.The main adverse reactions were grade 0-2,and no serious adverse reactions occurred.The quality of life benefit was 34.7%(17/49),in which 3 cases were significantly improved,14 cases were improved,29 cases were stable and 3 cases were decreased.Conclusion In the second-line treatment of advanced NSCLC patients,Nab-P monotherapy has obvious effects,which can reduce the occurrence of adverse reactions during the survival of patients,and has a good effect on improving the quality of life and health and prolonging survival of patients.It is worthy of clinical promotion and application.

关 键 词：白蛋白结合型紫杉醇 二线治疗 晚期非小细胞肺癌 疗效 

分 类 号：R734.2[医药卫生—肿瘤]